Connect with us

BUSINESS

Zelira Therapeutics Ltd (OTCMKTS:ZLDAF) Signing Nonbinding Agreement With Levin Growing To Develop Cannabinoid Based Chronic Pain Treatment

Published

on

Zelira Therapeutics Ltd (OTCMKTS:ZLDAF) has signed a nonbinding agreement with Levin Growing Pty Ltd for the establishment of a development partnership.

Partnership to develop chronic pain treatment

The company will partner with the Melbourne-based medical cannabis firm to develop a proprietary cannabinoid-based chronic pain treatment in retired and amateur athletes studies, retired athletes are likely to experience chronic pain related to conditions like anxiety and depression due to injuries and physical exertion over lengthy periods. Although there is limited clinical data on medical cannabis as an effective and safe targeted treatment option the cannabinoid-based therapy is likely to benefit retired athletes significantly.

Partnership between Zelira and Levin seeks to conduct clinical trials to address this unmet need. They will undertake the trial at the expense of Levin to evaluate the efficacy and safety of a novel cannabinoid formulation customized for sports-associated chronic pain. The collaboration will exploit the leading intellectual property as well as expertise of Zelira in medical cannabis clinical design. The targeted approach offers a chance to develop a leading brand addressing this widespread and specific unmet need.

Zelira to control marketing rights for North and South America

After the Heads of Agreement becomes binding, Zelira will license a particular formulation to Levin supporting the chronic pain trial in retired sportsmen. Zelira will design and co-ordinate the clinical study with funding from Levin. The study is an expansion of the strategic interests of Zelira in chronic pain. Zelira will control commercialization rights in South America and North America while Levin will retain rights to the rest of world markets.

Levin Chairman, Matt Syme, stated that they are thrilled in the partnership with Zelira, one of the top medical cannabis companies. Syme indicated that the company’s advisory board member and sports administrator, James Brayshaw, has identified various retired athletes suffering from chronic pain. He added that the clinical expertise of Zelira and Levin’s focus on medical cannabis science as a chronic pain treatment gives hope of having a non-addictive paint relieve alternative.

BUSINESS

The E-Commerce Arm Of American Green Inc (OTCMKTS:ERBB) Accepts Payments For Its Hemp And CBD Products In Bitcoins (BTC)

Published

on

The e-commerce platform of American Green Inc (OTCMKTS:ERBB) will start accepting payments for its cannabidiol and hemp products in Bitcoin (BTC) beginning March 2021. Its existing and new customers can make use of this facility to acquire their favorite CBD products.

Bitcoin payment assumes significance

Vice President (Worldwide sales) of American Green, Kevin Davis, said the addition of Bitcoin as a valid payment option improves the company’s ability to transact across the world and in the US. It assumes significance because the company targets to expand its presence in the international markets in 2022.

Foresees improved sales growth

American Green is posting significant growth YoY. Cryptocurrencies additions such as the Bitcoin payment option will improve hemp and cannabidiol products’ sales.

The acceptance of Bitcoin protects global customers and simplifies international transactions by eliminating complications like currency fluctuations in cross-border transactions. It also eliminates credit card interoperability issues and internet security problems. After the transaction, all the bitcoins are converted into equivalent US$ and eliminates the volatility associated with cryptocurrencies.

American Green posted record-high revenues in H2 2020. Its Phoenix-based cannabis grows management operation – Sweet Virginia, reported record revenues of $892,265 (up 15.41% YoY) in H2 2020. The company also reported an increase of 24.5% YoY in profits to $636848 during this period from its grow management operation.

David Gwyther, president of American Green, said the company is excited to report record growth. It is on the backdrop of putting significant efforts during difficult times of coronavirus. Customers’ trust in its products also helped the company to post double-digit growth.

Its online CBD division posted an increase of 10% in revenues in H2 2020. The company also commenced selling its CBD products through e-commerce giant – Amazon a few months back. It will soon add additional products to the Amazon platform.

Gwyther said American Green foresees great opportunities for its CBD and hemp products in Arizona and across the nation. It will capitalize on these emerging opportunities to boost growth soon and offer rich dividends to investors.

American Green entrusted the expansion responsibility to Gierczyk Architects for 20,000 sq. Ft. Cannabis Grow operations. It also plans to add 16,000 sq. Ft. to improve total net annual revenues to $7 million.

Continue Reading

BUSINESS

CLS Holdings USA Inc (OTCMKTS:CLSH) Posts Revenues Of $1.48 Million In January 2021: Strong Momentum At An Extraction Facility In North Las Vegas

Published

on

In January 2021, CLS Holdings USA Inc (OTCMKTS:CLSH) reports revenues of $1.48 million (up 28.5% YoY) from its subsidiaries based in North Las Vegas.

Makes new strides in sales growth

CLS is expanding its operations by developing a new division and introducing innovative products at City Trees. The company also improved sales at its Oasis Cannabis. All these initiatives helped the company to make new strides in its sales growth in January 2021.

Rolls out toll processing division

CLS inaugurated a toll processing division for its City Trees called Trichome Harvest Company on January 26, 2021. Trichome specializes in hydrocarbon and ethanol extraction services for third parties. City Trees introduced innovative vape products in February 2021.

In 2020, City Trees held 5th position in the vapes segment in Nevada. It also commands the number one slot in the production of tinctures. COO of CLS, Andrew Glashow, said the company focuses on providing diverse products at affordable rates at Oasis and City Trees. It also serves the local customers through its extraction facility. The company expects to see great momentum in the coming months.

The current market penetration of City Trees in Nevada is over 70%. City Trees manufactured nine distillate varieties, which are available in syringes, vape pens, and cartridges. Nevada-based dispensaries bought 11,378 units as of February 2021.

Inducts a new director

CLS added a new director – Ross Silver, to its director board. CEO of CLS, Jeffrey Binder, said he is excited to welcome Ross into the director board. Ross is a perfect fit into the company with his previous experience as an analyst, advisor, and leader. He is an invaluable asset to support the growth of CLS going forward.

With a finance background, Ross established an investment advisor company – Sylva International, in 2016 in Oregon. He also established Vista Partners, an independent equity research company, and a hedge fund.

Ross said CLS positions itself as a leading player in cannabis retail and production. He is pleased to join the CLS team, which is making consistent strides in growth and posting improvement in revenues YoY. CLS is yearning to expand its presence in the cannabis industry of Nevada.

Continue Reading

BUSINESS

Revive Therapeutics Ltd (OTCMKTS:RVVTF) Acquires Full IP Rights to Psilocybin From The Subsidiary Of Newscope Capital Corporation (OTCMKTS:PHRRF)

Published

on

Revive Therapeutics Ltd (OTCMKTS:RVVTF) acquired IP to Psilocybin of PharmaTher Inc., which is a subsidiary of Newscope Capital Corporation (OTCMKTS:PHRRF), for CAD 10 million.

Revive Therapeutics will pay $3 million in cash on concluding the deal to Newscope. It will issue its securities for an additional $4 million of the transaction. The company will pay the balance of $3 million either in stock or cash on meeting certain milestones such as receipt of orphan drug designation for its Psilocybin from the US FDA to treat cancer, traumatic brain injury, and stroke.

Advances psilocybin platform to treat neurological disorders

CEO of Revive Therapeutics, Michael Frank, said the takeover of Psilocybin strengthens its position to build OTF (oral thin film) products together with the University of Wisconsin-Madison. Revive Therapeutics can advance the psilocybin platform to address unmet clinical requirements in cancer, health, and neurological disorders.

CEO of Newscope, Fabio Chianelli, said the company is excited to enter a pact with Revive Therapeutics for its psilocybin program. Revive Therapeutics is already an established leader in the development of psilocybin pharmaceuticals.

An update on the evaluation of Bucillamine

Revive Therapeutics issued an update on the phase 3 clinical study of Bucillamine. The company is evaluating its efficacy and safety in patients suffering from moderate to mild coronavirus. It plans to expand the clinical trial to 50 clinical sites from the present 14 sites for the next enrollment study requirements in Q2 2021 with the recent financial support of $23 million.

It is a randomized, placebo-controlled, and double-blinded clinical trial. In this trial, the efficacy and safety data will be analyzed at each analysis time point of 400, 210, 800, and 600 completed patients and reported to the DSMP (Data and Safety Monitoring Board).

An independent DSMP will review the data and recommend appropriate changes to the study or stop the trial in serious safety concerns. Today, DSMP does not find any adverse safety concerns in the interim report involving 210 patients.

Michael said the company is additional clinical sites to satisfy the enrollment targets with the recent funding. It helps the company to satisfy the needs of the FDA and seek EUA approval.

Continue Reading

Trending Stories